Table 2.
Correlations between Lp-PLA2, sPLA2 and clinical parameters in newly diagnosed type 2 diabetes
| Lp-PLA2 (ng/ml) | sPLA2 (ng/ml) | |
|---|---|---|
| Body mass index (kg/m2) | r = 0.121, P = 0.311 | r = 0.123, P = 0.311 |
| Waist circumference (cm) | r = 0.023, P = 0.846 | r = 0.243, P = 0.043* |
| Systolic pressure (mmHg) | r = 0.080, P = 0.460 | r = 0.046, P = 0.677 |
| Diastolic pressure (mmHg) | r = 0.077, P = 0.472 | r = 0.079, P = 0.467 |
| HbA1c (%) | r = 0.283, P = 0.020* | r = 0.076, P = 0.545 |
| Total cholesterol (mmol/L) | r = 0.224, P = 0.070 | r = 0.147, P = 0.247 |
| Triglyceride (mmol/L) | r = 0.106, P = 0.448 | r = 0.078, P = 0.584 |
| HDL-C (mmol/L) | r = 0.240, P = 0.072 | r = 0.176, P = 0.199 |
| LDL-C (mmol/L) | r = 0.269, P = 0.029* | r = 0.177, P = 0.162 |
| HOMA-IR | r = 0.309, P = 0.037* | r = 0.506, P < 0.01** |
| HOMA-β | r = −0.116, P = 0.353 | r = −0.050, P = 0.670 |
| IVGTT AUCIns | r = −0.012, P = 0.294 | r = −0.038, P = 0.742 |
| IVGTT AUCPG | r = 0.120, P = 0.338 | r = 0.028, P = 0.809 |
| AIR3–5 | r = −0.029, P = 0.815 | r = −0.006, P = 0.961 |
| △Ins30/△G30 | r = −0.023, P = 0.855 | r = −0.055, P = 0.633 |
| OGTT AUCIns | r = −0.088, P = 0.483 | r = −0.055, P = 0.635 |
| OGTT AUCPG | r = 0.049, P = 0.688 | r = 0.042, P = 0.709 |
| MBCI | r = −0.099, P = 0.427 | r = −0.206, P = 0.073 |
| White blood cells (×109/L) | r = 0.137, P = 0.262 | r = 0.029, P = 0.796 |
| Free fatty acid (umol/L) | r = 0.167, P = 0.184 | r = 0.096, P = 0.408 |
| hsCRP (mg/L) | r = 0.023, P = 0.852 | r = 0.149, P = 0.189 |
Abbreviations: HbA1c hemoglobin A1c, IVGTT AUC Glu the areas under the curve of glucose in intravenous glucose tolerance test, OGTT AUC Glu the areas under the curve of glucose in oral glucose tolerance test, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, hsCRP high sensitivity C reactive protein; HOMA-IR, IAI, QUICKI and ISI ced are indicators of insulin sensitivity (HOMA-IR = FPG × FIns/22.5; IAI = 1/(FIns × FPG); QUICKI = 1/(lgFPG + lgFIns); ISIced = MCR/LgMSI, MCR = M/MG, MG = (FPG + Glu30 min + Glu60 min + Glu120 min)/4, MSI = (FIns + Ins30 min + Ins60 min + Ins120 min)/4, M = 75000/120 + (FPG - Glu120 min) × 1.15 × 180 × 0.19 × body weight/120), HOMA-β, AIR 3–5 ∆Ins30/∆G30, MBCI, IVGTT AUCIns and OGTT AUCIns are indicators of island function (HOMA-β = 20 × FIns/(FPG - 3.5); AIR3–5 is calculated as the average increase of plasma insulin between the 3rd or 5th minute and the base line in IVGTT; ∆Ins30/∆G30 = (Ins30min - FIns)/(Glu30min - FPG); MBCI = (FPG × FIns)/(Glu120min + Glu60min - 7); AUCIns, the area under the curve (AUC) of insulin, IVGTT AUCIns = (3 × FINS+ 5 × INS3+ 4 × INS5+ 5 × INS7+ 3 × INS10)/2, OGTT AUCIns = (FINS + 2 × INS30+ 3 × INS60+ 4 × INS120+ 2 × INS180)/4; all the indicators regarding to β cell function were respectively divided by HOMA-IR to guarantee from interference of insulin resistance), Lp-PLA 2 lipoprotein-associated phospholipase A2, sPLA 2 secretory phospholipase A2
Values of P < 0.05 are statistically significant